For U.S. Healthcare Professionals Only
Prescribing Information
Important Safety Information  |   Prescribing Information For U.S. Healthcare Professionals Only

Important Safety Information: SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One. View More

A A A

Billing Codes

To obtain reimbursement for Synvisc-One® and SYNVISC®, you must submit a property coded claim form. Below are the billing codes commonly used for Synvisc-One and SYNVISC and its administration.

Synvisc-One and SYNVISC Billing Codes
ICD-9-CM
715.16 Osteoarthritis, localized, primary, lower leg
715.26 Osteoarthritis, localized, secondary, lower leg
715.36 Osteoarthritis, localized, unspecified as to primary or secondary, lower leg
715.96 Osteoarthritis, localized, unspecified whether generalized or localized, lower leg
NDC
58468-0090-01 SYNVISC
58468-0090-03 Synvisc-One
HCPCS
J7325 For Synvisc-One and SYNVISC, per 1mg
Synvisc-One 48 in Units field of CMS-1500 Claim form or electronic equivalent
SYNVISC 16 in Units field of CMS-1500 Claim form or electronic equivalent
CPT
20610 Arthrocentesis, major joint or bursa * Include modifiers -RT, -LT or 50 (bilateral)
99211 to 99215 Office visit for established patients
99201 to 99205 New patient office or other outpatient visit
Revenue Codes (used in hospital setting only)
R636 Drugs requiring detailed coding
510 Clinic visit

Providers are responsible for the selection of appropriate codes depending on clinical diagnosis. Information in the above table provides a general framework for understanding possible coding alternatives. It should not be used as a substitute for a healthcare professional's own judgment.

Providers retain sole responsibility for determining reimbursement and insurance issues related to their patients and for ensuring the accuracy of their claim submissions. Sanofi cannot be responsible for failure of a provider to obtain reimbursement.

Reimbursement
Resources

Learn how Sanofi
Patient Connection is
here to support you.

Specialty
Pharmacy Forms

Find prior authorization
forms and other
important forms.

Indication

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children (≤21years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

For SYNVISC

In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

For Synvisc-One

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc-One